Prophylactic recombinant epoetin alfa markedly reduces the need for blood transfusion in patients with metastatic melanoma treated with biochemotherapy Journal Article
| Authors: | Wolchok, J. D.; Klimek, V. M.; Williams, L.; Chapman, P. B. |
| Article Title: | Prophylactic recombinant epoetin alfa markedly reduces the need for blood transfusion in patients with metastatic melanoma treated with biochemotherapy |
| Abstract: | Treatment of metastatic melanoma with biochemotherapy results in the rapid onset of anemia, requiring blood transfusion in 9 of 13 (69%) patients. Prophylactic use of weekly subcutaneous recombinant epoetin alfa eliminated the need for transfusion in all but 1 of 21 (5%) patients. |
| Keywords: | clinical article; controlled study; clinical trial; cisplatin; alpha interferon; dacarbazine; interleukin 2; melanoma; quality of life; controlled clinical trial; erythropoietin; anemia; vinblastine; neoplasm metastasis; blood transfusion; drug therapy; recombinant erythropoietin; cost-benefit analysis; hematinics; biochemotherapy; epoetin alfa; humans; human; priority journal; article |
| Journal Title: | Cytokines Cellular and Molecular Therapy |
| Volume: | 5 |
| Issue: | 4 |
| ISSN: | 1368-4736 |
| Publisher: | Taylor & Francis Group |
| Date Published: | 1999-12-01 |
| Start Page: | 205 |
| End Page: | 206 |
| Language: | English |
| PUBMED: | 10850383 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Export Date: 16 August 2016 -- Source: Scopus |
Citation Impact
Related MSK Work